Learn More
Invitrogen™ Vivofectamine™ VF233 IM LNP Composition in Ethanol
Description
Vivofectamine VF233 IM LNP Composition in Ethanol is a reagent for use in the creation of lipid nanoparticles (LNPs) for in vivo delivery of mRNA via intramuscular (IM) route. It can be used for basic research applications such as prophylactic and cancer vaccines.
Features and benefits
- Optimized formulation for intramuscular delivery
- Immunogenicity benchmarked to ionizable lipids used in leading clinical-stage or FDA-approved drugs
- Safety characterization in vivo
- Flexibility in choice of formulation device and method
Vivofectamine VF233 IM LNP Composition in Ethanol is a pre-mixed solution with an optimized ratio of an ionizable lipid and helper lipids. It can be used with various formulation devices and methods.
Vivofectamine VF233 IM LNP Composition in Ethanol is a Research Use Only reagent for use in basic research. If you are looking for an LNP solution for drug development purposes with a path to clinical and commercial licensing and supply, please submit a contact us request at our Vivofectamine webpage to access our Vivofectamine Delivery Solutions Drug Developer Portfolio.
Vivofectamine VF233 IM LNP Composition in Ethanol is an animal origin-free product.
Specifications
Specifications
| Classification | Animal origin-free (AOF) |
| Delivery Type | In vivo |
| Format | Tube |
| Transfection Technique | Lipid-based Transfection, Lipid Nanoparticles, LNPs |
| Species | Mouse |
| Formulation | Ratio-optimized mixture of lipid solution in ethanol |
| Product Line | Vivofectamine |
| Product Type | Reagent |
| Quantity | 1 mL |
| Shipping Condition | Dry Ice |
| Show More |
For Research Use Only. Not for use in diagnostic procedures.
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.